60%Confidence
0Views
SEC EDGARSource
2026-03-05Date
Summary
Silence Therapeutics filed an 8-K, likely related to clinical updates, partnerships, or financial results in the biotech sector. Such disclosures are critical for evaluating the company's pipeline progress and valuation.
Actionable: Examine the 8-K for any material news on SLN's drug development or corporate milestones.
AI Confidence: 60%
Data Points
companySilence Therapeutics plc (SLN, SLNCF) (CIK 0001479615)
form8-K
date2026-03-05
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now